SGH
MDGL icon

Sivik Global Healthcare’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sivik Global Healthcare’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,000
Closed -$1.51M – 53
2025
Q2 		$1.51M Buy
+5,000
New +$1.49M 0.41% 44

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Sivik Global Healthcare's MDGL Position: Q3 2025 in Review

Sivik Global Healthcare sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 5,000 shares — an estimated $1.51M sold.

Sivik Global Healthcare first reported a position in MDGL in Q2 2025 and held it in 1 quarter. The position peaked at $1.51M in Q2 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Sivik Global Healthcare reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sivik Global Healthcare sold 5,000 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $1.51M.
  • Sivik Global Healthcare first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Sivik Global Healthcare's Madrigal Pharmaceuticals position peaked at $1.51M in Q2 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Sivik Global Healthcare's 13F filing for Q3 2025, filed 23 Oct 2025.